KCR CEO, Mike Jagielski, told us the decision to move offices was an easy one to make, “Boston is where money and research meet on the East coast,” he said. “KCR needs to be part of the East Coast R&D hub.”
The facility will be offering “the full KCR Trial Execution service spectrum,” Jagielski explained, beginning with clinical operations, project management, and data management.
The CRO has seen the greatest demand from biotech in Phase I (oncology), Phase II, and Phase III, “supporting US biotech with the execution of trials between Europe and US,” Jagielski added.
“We are just glad to be in Boston finally. We’ve worked on US ground for many years now, but this piece was somewhat missing.”
The grand opening is planned for June 2017.